CDBT yields 2000.00% · JNJ yields 2.14%● Live data
📍 CDBT pulled ahead of the other in Year 1
Combined, CDBT + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CDBT + JNJ for your $10,000?
China Dasheng Biotechnology Company, together with its subsidiaries, engages in the production, marketing, and distribution of bacteria based products used as additives for livestock feed and crop cultivation in the People's Republic of China. It provides artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends; and biological preservatives. The company offers AM/HM bacteria based additives for crops, including Bulgaria lactobacillus, beer microzyme, and dark red spirilla used to increase the beneficial microorganism colonies in soil; inhibit the reproduction of harmful fungi and putrefactive bacteria; and to improve nutrient absorption and reduce crop and livestock diseases. It also provides AM/HM bacteria based additives for livestock feed, which softens the livestock feed and restrain the growth and reproduction of pathogenic bacteria, as well as supplies beneficial nutriments, including organic acid, vitamins, enzyme, antibiotics, mycelium protein, and other growth-enhancing substances that balance the nutrients in the feed. In addition, the company offers FGW bacterial based preservatives that preserve animal specimens for scientific research; and preserve the freshness for agricultural produce. Further, it provides bacteria based fertilizer for application on plants, such as vegetable and fruit leaves. Additionally, China Dasheng Biotechnology Company engages in residential and commercial real estate investment. The company was formerly known as Max Nutrition, Inc. and changed its name to China Dasheng Biotechnology Company in March 2008. China Dasheng Biotechnology Company is based in Lanzhou, China.
Full CDBT Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.